These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 164507)

  • 1. Partial characterization of a soluble antigen preparation from cells infected with human cytomegalovirus: properties of antisera prepared to the antigen.
    Waner JL
    J Immunol; 1975 May; 114(5):1454-7. PubMed ID: 164507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus antigenic heterogeneity can cause false-negative results in indirect hemagglutination and complement fixation antibody assays.
    Faix RG
    J Clin Microbiol; 1985 Nov; 22(5):768-71. PubMed ID: 2997271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of polyclonal antisera against cytomegalovirus and varicella-zoster virus by use of affinity-purified viral antigens.
    Ukkonen P
    APMIS; 1989 Mar; 97(3):267-73. PubMed ID: 2540778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.
    Rasmussen LE; Nelson RM; Kelsall DC; Merigan TC
    Proc Natl Acad Sci U S A; 1984 Feb; 81(3):876-80. PubMed ID: 6199788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisera to human cytomegalovirus produced in hamsters: reactivity in radioimmunoassay and other antibody assay systems.
    Forghani B; Schmidt NJ; Lennette EH
    Infect Immun; 1976 Nov; 14(5):1184-90. PubMed ID: 185151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisera to human cytomegaloviruses prepared in the guinea pig: specific immunofluorescence and complement fixation tests.
    Huang YT; Huang ES; Pagano JS
    J Immunol; 1974 Feb; 112(2):528-32. PubMed ID: 4360544
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of antigenic diversity among human cytomegaloviruses by kinetic neutralization tests with high-titered rabbit antisera.
    Waner JL; Weller TH
    Infect Immun; 1978 Jul; 21(1):151-7. PubMed ID: 213383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and characterization of monoclonal antibodies specific for a glycosylated polypeptide of human cytomegalovirus.
    Kim KS; Sapienza VJ; Chen CM; Wisniewski K
    J Clin Microbiol; 1983 Aug; 18(2):331-43. PubMed ID: 6194174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for early nuclear antigens in cytomegalovirus-infected cells.
    Geder L
    J Gen Virol; 1976 Aug; 32(2):315-9. PubMed ID: 190342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirmation of human cytomegalovirus by reverse passive hemagglutination with monoclonal antibodies reactive to the major glycosylated peptide (GP-66).
    Kim KS; Sapienza V; Chen CM
    J Clin Microbiol; 1986 Sep; 24(3):474-7. PubMed ID: 2428828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA.
    Fletcher JM; Prentice HG; Grundy JE
    J Immunol; 1998 Sep; 161(5):2365-74. PubMed ID: 9725232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-fixing antigen of human cytomegaloviruses.
    Kim KS; Moon HM; Sapienza VJ; Carp RI
    J Infect Dis; 1977 Feb; 135(2):281-8. PubMed ID: 190330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of early antigens in nuclei of cells infected with cytomegalovirus or herpes simplex virus type 1 and 2 by anti-complement immunofluorescence, and use of a blocking assay to demonstrate their specificity.
    Giraldo G; Beth E; Hämmerling U; Tarro G; Kourilsky FM
    Int J Cancer; 1977 Jan; 19(1):107-16. PubMed ID: 64461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M; Shiraki A; Daikoku T; Oyama Y; Yoshida Y; Shiraki K
    J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic polypeptides of 3 reference strains recognized by sera from cytomegalovirus (CMV) infected patients.
    Lery X; Chardonnet Y; Revillard JP
    Dev Biol Stand; 1982; 52():359-66. PubMed ID: 6187615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-day assay for human cytomegalovirus applicable to serum neutralization tests.
    Waner JL; Budnick JE
    Appl Microbiol; 1973 Jan; 25(1):37-9. PubMed ID: 4346976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of an early cytomegalovirus antigen with two-color quantitative flow cytometry.
    Elmendorf S; McSharry J; Laffin J; Fogleman D; Lehman JM
    Cytometry; 1988 May; 9(3):254-60. PubMed ID: 2837368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early nuclear antigen as DNA-binding protein in cytomegalovirus-infected cells.
    Gergely L; Czeglédy J; Váczi L
    Intervirology; 1980; 13(6):352-6. PubMed ID: 6252117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced recovery of cytomegalovirus in conventional tube cultures with a spin-amplified adsorption.
    Oefinger PE; Shawar RM; Loo SH; Tsai LT; Arnett JK
    J Clin Microbiol; 1990 May; 28(5):965-9. PubMed ID: 2161870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus.
    Rasmussen L; Mullenax J; Nelson R; Merigan TC
    J Virol; 1985 Aug; 55(2):274-80. PubMed ID: 2410626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.